Listed on the Nasdaq Global Market under the ticker symbol "SCTX," and raised capital to fund the initial clinical development of STX-1150, STX-1200, and STX-1400
Continued enrollment in first-in-human Phase 1 clinical trial of STX-1150, the Company's epigenetic silencing therapy for LDL-C lowering, with initial clinical data expected in the first half of 2027
Expanded strategic collaboration with Sanofi, providing access to the Company's ELXR silencing technology and further validating its platform innovation
Reinforced leadership in genetic medicines through presentations and a new publication highlighting advances across the Company's cardiovascular pipeline and proprietary epigenetic silencing and gene-editing technologies
Cash, cash equivalents, and marketable securities of $174.2 million as of September 30, 2026, provide funding into the first half of 2029
ALAMEDA, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics" or "the Company") (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, today reported financial results for the third quarter ended September 30, 2026, and provided recent corporate and pipeline updates.
During the third quarter, Scribe continued to build on the momentum generated by its successful initial public offering. The Company completed an upsized IPO, welcomed leading public healthcare investors to its shareholder base, and broadened analyst coverage, positioning the Company to execute against its long-term vision of developing durable genetic medicines for highly prevalent cardiometabolic diseases.
"This is a period of continued execution for Scribe, marked by the successful completion of our IPO and expansion of our collaboration with Sanofi to include the epigenetic silencing technology. Together, these milestones strengthen our foundation as we work to translate the potential of our technologies into meaningful medicines for patients," said Benjamin Oakes, Ph.D., co-founder and Chief Executive Officer of Scribe Therapeutics.
Pipeline Highlights
STX-1150: In vivo epigenetic silencing therapy for low-density lipoprotein cholesterol (LDL-C) lowering in ongoing Phase 1 clinical trial
-- STX-1150 utilizes Scribe's Epigenetic Long-term X Repressor (ELXR)
technology to silence PCSK9, a genetically and clinically validated
target for LDL-C lowering.
-- STX-1150 is designed to address a major limitation of current LDL-C
lowering approaches and is positioned to recapitulate the
cardioprotective effects of human genetics.
-- Current LDL-C lowering therapies are limited by poor persistence
and adherence, with studies showing that 50% to 70% of patients
discontinue treatment within one year.
-- STX-1150 is designed to overcome these challenges by providing
potent, ultra-long-lasting LDL-C reduction.
-- STX-1150 aims to mimic the protective cardiovascular profile
observed in individuals with naturally occurring PCSK9
loss-of-function variants, who have been reported to have 28%
lower mean LDL-C levels and up to 88% lower coronary heart disease
risk. By recapitulating the effects of this naturally occurring
protection, STX-1150 has the potential to shift LDL-C management
from burdensome chronic treatment to long-term prevention.
-- Presented late-breaking data at the American Heart Association (AHA)
Scientific Sessions 2026 meeting supporting STX-1150 for
ultra-long-lasting LDL-C lowering after a single dose without permanently
altering DNA.
-- A single administration at a therapeutically relevant dose of 0.75
mg/kg demonstrated durable LDL-C reductions of greater than 50%,
sustained for two years, with liver enzyme profiles comparable to
saline controls in non-human primates $(NHP)$.
-- In an additional NHP study, re-dosing of STX-1150 enabled
progressively greater LDL-C lowering while maintaining
tolerability.
-- First-in-human Phase 1 clinical trial of STX-1150, initiated in mid-2026,
is ongoing. Clinical data expected in the first half of 2027.
-- The Phase 1 study will evaluate the safety, tolerability,
pharmacokinetics, and pharmacodynamics of STX-1150 in adults with
elevated low-density lipoprotein cholesterol and increased risk of
atherosclerotic cardiovascular disease (ASCVD).
-- Scribe anticipates reporting initial clinical data, including
safety, tolerability, and LDL-C lowering activity, from the single
ascending dose portion of the STX-1150 Phase 1 trial in the first
half of 2027.
STX-1200: In vivo gene editing designed to provide curative lowering for patients with genetically elevated Lp(a)
-- Presented data at the AHA Scientific Sessions 2026 meeting highlighting
STX-1200, which targets LPA utilizing X-Editor $(XE)$, Scribe's highly
engineered gene editing technology.
-- STX-1200 is designed to lower lipoprotein(a) (Lp(a)) in patients
with genetically elevated Lp(a) and associated ASCVD risk. In
preclinical studies, STX-1200 surrogates achieved greater than 95%
Lp(a) reduction in NHPs.
Corporate Highlights
-- Nasdaq listing: The Company's common stock began trading on the Nasdaq
Global Market on July 24, 2026, under the ticker symbol "SCTX." Scribe
upsized its initial public offering and priced at the high end of the
range. The Company also completed a concurrent private placement to
Sanofi at the IPO price.
-- Approximately $155.5 million in aggregate gross proceeds: Capital raised
from the IPO, the full exercise of the underwriters' option, and the
concurrent private placement totaled $155.5 million before underwriting
discounts, commissions, and offering expenses.
-- Funding into the first half of 2029: Based on Scribe's current operating
plan, the Company believes its cash, cash equivalents, and marketable
securities will be sufficient to fund its operating expenses and capital
expenditure requirements into the first half of 2029.
-- Expanded strategic collaboration with Sanofi to include Scribe's ELXR
epigenetic silencing technology: Scribe expanded its multi-year research
collaboration with Sanofi, providing Sanofi access to Scribe's
proprietary ELXR epigenetic silencing technology in addition to its XE
gene-editing technology and extending Sanofi's nomination period for
target selection under the license agreement.
Platform and Scientific Leadership
-- Presented advances in ELXR epigenetic silencing technology demonstrating
improvements in potency and specificity.
-- At the European Society of Gene and Cell Therapy (ESGCT) Congress,
Scribe presented findings demonstrating a novel approach to
epigenetic silencing termed "sequential proofreading" that reduces
unintended DNA methylation by 10-fold and enhances potency by at
least 4-fold.
-- These advances highlight ELXR's differentiated potency and
precision and underpin the Company's lead asset STX-1150,
currently in the clinic for LDL-C lowering.
-- New data highlight advances in industry-leading genome editing potency
and specificity of the Company's engineered XE gene-editing technology.
-- The Company's comprehensive and iterative molecular engineering
approach transformed CRISPR-CasX, a naturally occurring bacterial
immune system, into its highly engineered XE gene-editing
technology for therapeutic development. This foundational work
underpins the Company's STX-1200 and STX-1400 programs and has
contributed to the development of its clinical-stage STX-1150
program, demonstrating the broader applicability of Scribe's
engineered platforms for cardiovascular disease.
-- The engineered XE technology exhibited >100-fold improvements in
editing activity compared with naturally occurring CasX and
demonstrated its ability to potently edit genes in vivo across
muscle, eye, liver, and brain tissue.
-- XE demonstrated the potential for a broader therapeutic window by
achieving saturating editing across two distinct genomic targets
in NHP liver, with no detectable off-target editing in primary
human liver cells at 10-fold supersaturating doses.
-- These findings demonstrate that XE is more potent at lower doses
than comparable preclinical data from Cas9-based therapies that
are now in clinical testing.
-- A manuscript has been submitted to bioRxiv and will be available
in the Publications section of the Company's website once posted.
Third Quarter 2026 Financial Results
-- Cash position: Cash, cash equivalents, and marketable securities were
$174.2 million as of September 30, 2026, compared to $43.0 million as of
June 30, 2026. The increase was primarily driven by approximately $140.2
million of net proceeds from the July 2026 IPO and concurrent private
placement, partially offset by cash used in operations. Cash, cash
equivalents, and marketable securities as of September 30, 2026, are
expected to provide funding into the first half of 2029.
-- Collaboration revenue: For the three months ended September 30, 2026,
collaboration revenue totaled $1.6 million, compared to $1.9 million for
the three months ended June 30, 2026. The decrease was primarily
attributable to lower revenue recognized under the Eli Lilly
collaboration due to lower reimbursable research and development
activities incurred in the period.
-- Research and development expenses: For the three months ended September
30, 2026, research and development expenses totaled $8.3 million,
compared to $8.8 million for the three months ended June 30, 2026. The
decrease was primarily attributable to lower employee-related and
external research and development expenses and the recognition of grant
funding from the California Institute for Regenerative Medicine (CIRM) as
an offset to research and development expenses.
-- General and administrative expenses: For the three months ended September
30, 2026, general and administrative expenses totaled $4.2 million,
compared to $2.5 million for the three months ended June 30, 2026. The
increase was primarily attributable to higher stock-based compensation
expense and increased professional services fees and other costs
associated with operating as a public company.
-- Net loss: For the three months ended September 30, 2026, net loss was
$9.9 million, or $0.68 per basic and diluted share, compared to a net
loss of $6.5 million for the three months ended June 30, 2026.
About Scribe Therapeutics Inc.
Scribe Therapeutics is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Leveraging its CRISPR by Design(TM) approach and nature's blueprint for improved cardiovascular health, Scribe's initial programs focus on addressing the key drivers of ASCVD such as elevated LDL-C, lipoprotein(a), and triglycerides. The company's lead candidate, STX-1150, is a novel liver-targeted therapy designed to epigenetically silence the PCSK9 gene and reduce LDL-C levels without inducing permanent DNA changes. To broaden and accelerate the impact of its engineered CRISPR technologies for patients, Scribe has formed strategic collaborations with world-leading pharmaceutical companies including Sanofi and Eli Lilly. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is advancing scalable, transformative, and preventative genetic medicines with the goal of improving outcomes and democratizing access to the protective effects of beneficial human genetics. To learn more, visit www.scribetx.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release, including statements regarding Scribe's strategy, business plans and objectives; the therapeutic potential, safety, efficacy, durability, scalability and clinical or commercial prospects of Scribe's product candidates and technologies; the design, initiation, enrollment, conduct, timing and results of preclinical studies and clinical trials; the timing of clinical data and other anticipated milestones; the advancement of STX-1150, STX-1200, STX-1400 and other programs; the expected use and benefits of CIRM funding; and Scribe's expected cash runway and financial position are forward-looking statements. The words "aim," "anticipate," "believe," "continue," "could," "design," "estimate," "expect," "goal," "intend," "may," "plan," "potential," "seek," "should, " "target," "will" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Forward-looking statements are based on management's current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those described under the heading "Risk Factors" in Scribe's filings with the U.S. Securities and Exchange Commission, including its final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended, and future reports that Scribe may file with the SEC. Except as required by law, Scribe undertakes no obligation to update any forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events.
Investor Contact:
Investor Relations, Scribe Therapeutics
ir@scribetx.com
Media Contact:
Thermal for Scribe Therapeutics
media@scribetx.com
SCRIBE THERAPEUTICS INC.
Statement of Operations
(in thousands, except share and per share data)
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
------------------- ----------------------
2026 2025 2026 2025
Collaboration
revenue $ 1,636 $20,113 $ 5,787 $ 42,136
Operating expenses:
Research and
development 8,259 14,421 28,386 44,297
General and
administrative 4,239 3,531 10,084 12,863
------- ------ ------- -------
Total
operating
expenses 12,498 17,952 38,470 57,160
------- ------ ------- -------
Loss from operations (10,862) 2,161 (32,683) (15,024)
Interest income
and other
income, net 1,230 772 2,128 2,716
Interest expense -- (598) (875) (1,795)
Change in fair
value of
Convertible
Note -- (539) (1,585) 1,543
------- ------ ------- -------
Net loss before
provision for
income taxes (9,632) 1,796 (33,015) (12,560)
(Provision for) /
benefit from
income tax (231) (324) (672) 703
------- ------ ------- -------
Net loss $ (9,863) $ 1,472 $(33,687) $(11,857)
SCRIBE THERAPEUTICS INC.
Selected Balance Sheet Items
(in thousands, except share and per share data)
(Unaudited)
September 30, December 31,
--------------- ----------------
2026 2025
(in thousands)
Cash, cash equivalents and marketable
securities $ 174,230 $ 57,963
Total Assets 187,930 78,219
Total Liabilities 61,760 101,282
----------- ---------
Total stockholders' equity /
(deficit) $ 125,170 $ (143,419)
=========== =========
Comments